»  Introduction
Biotechnology has shown tremendous progress in the developed countries. Several developing countries now have well-developed biotechnology programs; they are approaching the leading edge of biotechnology applications and have significant research capacity.
There is substantial variation among developing countries in terms of their capacity to develop and use biological products.

Among all, some of the Asian countries try to consider biotechnology in their national priority list and Biotechnology is in the heart of their technology revolution. They have adopted strategies for harnessing the potential of biotechnology for their industrial development. The areas of applications both in pharmaceutical and agricultural sectors have widened, finding new horizons of economic growth.

We are proud to see that the Islamic Republic of Iran is achieved the 5th position among the Asian countries after Japan, South Korea, India and China.

Iran has focused on both agricultural and medicinal applications of biotechnology, and has developed significant infrastructure both in terms of production and advanced methods. Indeed, the share of CinnaGen in this ranking position is something that can not be ignored as being a trustable producer for molecular  biology reagents and recombinant biopharmaceuticals.

Since 1994, CinnaGen Co. has invested her resources in production of molecular biology reagents and related technologies that would meet the highest international standards. With such efforts, we have established processes to meet all quality criteria. R&D plays an important role in our policies for advancement. Using our expertise, we are constantly moving towards new products as well as improving the quality of our existing product lines. With dedication of our experts and collaboration with other research centers, we have expanded our product list to more than 70 items. Our product list is a reflection of some of the most strategic needs of different laboratories, biotech companies and pharmaceutical markets in the region.

CinnaGen Co. has founded in 1994 with the goal of manufacturing High-Tech products in biotechnology and related fields. Since its start of operations with 4 scientists, CinnaGen has grown to become the biggest Biopharma manufacturer and biotech exporter in the region. The concept was to be active in the research and development of new potent biotech-based products for covering regional market.

Enzymes, molecular biology reagents and PCR kits are the first products and then CinnaGen use its proprietary set of technologies to endow Monoclonal Antibodies for blood group typing. The next important step for CinnaGen was the entry to the therapeutic recombinant protein area.

Today the company prides itself in its innovative skills meeting today’s challenges. We focus our efforts on developing the biogenerics candidates in the areas of immunological diseases and oncology as well as providing contract research development services. The company is spending over 20 percent of its total turnover on R&D activities.

CinnaGen is strategically positioned to become and remain leading biotechnology company in the region. Our aim is to use our expertise to identify and acquire selected products, through strategic partnerships to promote sustainable development in human health.